TY - JOUR
T1 - Heterocyclic anticancer compounds
T2 - Recent advances and the paradigm shift towards the use of nanomedicine's tool Box
AU - Martins, Pedro
AU - Jesus, Joao
AU - Santos, Sofia
AU - Raposo, Luis R.
AU - Roma-Rodrigues, Catarina
AU - Baptista, Pedro Miguel Ribeiro Viana
AU - Fernandes, Maria Alexandra Núncio de Carvalho Ramos
N1 - FCT/MEC SFRH/BD/70202/2010 #
FCT/MEC PTDC/BBB-NAN/1812/2012 #
FCT/MECPEst-OE/QUI/UI0100/2013#
FCT/MEC UID/Multi/04378/2013 #
PY - 2015/9
Y1 - 2015/9
N2 - The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorization of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles.
AB - The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorization of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles.
KW - cancer therapy
KW - heterocyclic compounds
KW - oxygen and nitrogen-based heterocycles
KW - drug delivery
KW - nanomedicine
KW - METASTATIC BREAST-CANCER
KW - DRUG-DELIVERY SYSTEMS
KW - GOLD NANOPARTICLES
KW - IN-VITRO
KW - CELLULAR UPTAKE
KW - OVARIAN-CANCER
KW - ANTIPROLIFERATIVE ACTIVITY
KW - THERAPEUTIC APPLICATIONS
KW - TRIAZOLO-THIADIAZOLES
KW - LIPOSOMAL DOXORUBICIN
U2 - 10.3390/molecules200916852
DO - 10.3390/molecules200916852
M3 - Review article
C2 - 26389876
SN - 1420-3049
VL - 20
SP - 16852
EP - 16891
JO - Molecules
JF - Molecules
IS - 9
ER -